Opicapone use in patients with Parkinson’s disease with motor fluctuations: experience from a tertiary center
Objective: To assess effectiveness and safety profile of Opicapone in our cohort of patients with Parkinson’s disease (PD) who received this treatment. Background: Opicapone is…Subgroup analyses by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) of patients treated with levodopa inhalation powder 84mg or placebo to treat OFF symptoms in patients with Parkinson’s disease (PD)
Objective: An analysis of the proportion of patients who turned ON after levodopa inhalation powder (CVT-301) 84mg treatment vs placebo, compared across subgroups of patients…Personalization of deep brain stimulation using local field potentials to drive adaptive DBS: a case series
Objective: To observe chronically recorded local field potentials (LFPs) in patients receiving Deep Brain Stimulation (DBS) for Parkinson’s Disease (PD) and using an adaptive DBS…Non-motor fluctuations in People with Parkinson’s considering Deep Brain Stimulation surgery
Objective: In this study we examine non-motor symptom (NMS) fluctuations reported by People with Parkinson’s (PWP) pursuing Deep Brain Stimulation (DBS) surgery using the MDS…Case reports of first experiences worldwide with novel continuous oral levodopa dental pump in Parkinson’s Disease Patients
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of a novel continuous levodopa-carbidopa oral pump (LCOP) delivery system in patients with early PD. Background:…Psychometric characteristics of the Neuropsychiatric Fluctuation Scale
Objective: To evaluate the psychometric properties of the Neuropsychiatric fluctuation scale (NFS) for Parkinson’s disease (PD). Background: Neuropsychiatric fluctuations (NpsyF) in PD are frequent and…Quality of life and patient reported outcomes with subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 BeyoND study
Objective: To review quality of life and other patient reported outcomes data from the ND0612 BeyoND study. Background: ND0612 is in development as a continuous,…Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Data from patients who continued past one year in the BeyoND study
Objective: To report long-term safety and tolerability data from the ongoing BeyoND study (NCT02726386) for patients who continued treatment past the one-year primary endpoint. Background:…Collective expert perspectives on the use of safinamide as adjunctive therapy for Parkinson’s disease in Japan: Online-based Delphi approach
Objective: To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in…Basal forebrain contribution to cognitive deficits during medication “off” state in Parkinson’s disease
Objective: We sought to determine whether structural integrity of cholinergic Basal Forebrain (BF) was associated with subjective cognitive deficits experienced during medication “off” time Parkinson’s…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 23
- Next Page »